Takeda’s bid still has to go to a shareholder vote, which needs 75 percent approval or higher to go through. REUTERS/Arnd Wiegmann
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) Tuesday, the biggest yet in a wave of deals sweeping the drugs industry.The deal, struck on the last day Takeda had to make a firm bid, is around 46 percent cash and 54 percent stock, leaving Shire shareholders owning around half of the combination.Shire investors will receive $30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda American depositary shares for each share, valuing the offer at 48.17 pounds a share based on the latest price and exchange rate.The deal must get the support of 75 percent of Shire's voting shareholders.
FOLLOW THIS ARTICLE